- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jewel Mullen Discusses NASEM's Framework for an Equitable Distribution of a COVID-19 Vaccine
Recently released vaccine data indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). When vaccine doses first become available, who should be prioritized?
Recently released vaccine data from Pfizer, Moderna, and AstraZeneca indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). But all 3 vaccines are still a long way from becoming readily available to the wider public, prompting the question, who should be prioritized once doses become available?
To provide guidance on this front, the National Institutes of Health (NIH) and CDC requested The National Academies of Science, Engineering, and Medicine (NASEM) to construct a framework assisting US policy makers and global health communities to plan for an equitable allocation of a COVID-19 vaccine.
On this episode of Managed Care Cast, we speak with Jewel Mullen, MD, MPH, the associate dean for health equity and associate professor of population health and internal medicine at the University of Texas at Austin, Dell Medical School. Mullen is the former principal deputy assistant secretary for health in HHS and a member of the National Academies committee which developed the framework for vaccine allocation.
Mullen discusses criteria used to prioritize vaccine recipients, barriers to equitable distribution, and the role of misinformation in the push for an effective COVID-19 vaccine.
Listen above or through one of these podcast services:
Read more:
Pfizer Says Vaccine 90% Effective; Biden Team Announces COVID-19 Transition Panel
Study Backs Decision to Move Forward With Pfizer Vaccine Candidate
Moderna SARS-CoV-2 Vaccine Elicits Response in Older Adults
Dr Maura Abbott: Talk to Your Patients About Their Vaccine Fears
Dr Maura Abbott: COVID-19 Vaccine Development Process Is Safe Despite a Quicker Timeline
Dr Victoria Smith on Experience Taking Part in a COVID-19 Vaccine Trial
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
